

REMARKS

Currently claims 1-3, 5-7, 12, 14-17, 21 and 23 are pending. Applicants amended the claims to remove unintentional duplication, place them in a form appropriate to US practice, and to reduce the filing fee by, inter alia, removing multiple dependency. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Bonnie L. Deppenbrock

Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 21 April 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988

Express Mail Label No.: EV332065615US

Date of Mailing: 4/21/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson

Patty Wilson